{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:08:39Z","timestamp":1793761719319,"version":"4.6.1"},"reference-count":136,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.pharmthera.2009.05.008","type":"journal-article","created":{"date-parts":[[2009,6,3]],"date-time":"2009-06-03T08:33:19Z","timestamp":1244017999000},"page":"334-343","source":"Crossref","is-referenced-by-count":139,"title":["Kappa-opioid ligands in the study and treatment of mood disorders"],"prefix":"10.1016","volume":"123","author":[{"suffix":"Jr.","given":"William A.","family":"Carlezon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"B\u00e9guin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison T.","family":"Knoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2009.05.008_bib1","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1471-4159.1989.tb07398.x","article-title":"\u03b12-adrenergic, \u03ba-opiate, and P1-purinergic autoreceptors have mutually antagonistic effects: a new regulatory mechanism?","volume":"53","author":"Adamson","year":"1989","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib2","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/j.1471-4159.1989.tb08561.x","article-title":"Presynaptic KOR-opioid receptors on noradrenergic nerve terminals couple to G proteins and interact with the alpha 2-adrenoceptors","volume":"53","author":"Allgaier","year":"1989","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib3","first-page":"103","article-title":"Characterization of serotonergic mechanisms involved in the behavioural inhibition induced by 5-hydroxytryptophan in a modified light\u2013dark test in mice","volume":"9","author":"Artaiz","year":"1998","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1017\/S1461145701002632","article-title":"Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635","volume":"4","author":"Bagdy","year":"2001","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF00444692","article-title":"Evidence that the aversive effects of \u00b5-opioid antagonists and \u03ba-agonists are centrally mediated","volume":"98","author":"Bals-Kubik","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1517\/13543784.6.10.1351","article-title":"Novel developments with selective, non-peptidic KOR-opioid receptor agonists","volume":"6","author":"Barber","year":"1997","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(02)02274-4","article-title":"Sex-related differences in mechanical nociception and antinociception produced by mu- and kappa-opioid receptor agonists in rats","volume":"452","author":"Barrett","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib8","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.npp.1300811","article-title":"Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?","volume":"30","author":"Bart","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00213-005-0167-4","article-title":"Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats","volume":"183","author":"Beardsley","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib10","series-title":"Opioid Receptors and Antagonists: From Bench to Clinic","article-title":"Medicinal chemistry of kappa opioid receptor antagonists","author":"Beguin","year":"2008"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib11","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.bmcl.2005.03.113","article-title":"Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2)","volume":"15","author":"Beguin","year":"2005","journal-title":"Bioorgan Med Chem Lett"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib12","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1021\/jm025575g","article-title":"Identification of arodyn, a novel acetylated dynorphin A-(1\u201311) analogue, as a kappa opioid receptor antagonist","volume":"45","author":"Bennett","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004714-199502000-00008","article-title":"Buprenorphine treatment of refractory depression","volume":"15","author":"Bodkin","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF02245071","article-title":"Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay","volume":"115","author":"Broadbear","year":"1994","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib15","doi-asserted-by":"crossref","first-page":"29803","DOI":"10.1074\/jbc.M705540200","article-title":"Long-acting \u03ba opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase","volume":"282","author":"Bruchas","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2005-837763","article-title":"Use of nonprohibited hallucinogenic plants: increasing relevance for public health? A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage)","volume":"38","author":"Bucheler","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib17","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1038\/nprot.2007.441","article-title":"Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation","volume":"2","author":"Carlezon","year":"2007","journal-title":"Nature Protocols"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuropharm.2008.06.075","article-title":"Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis","volume":"56","author":"Carlezon","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib19","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1126\/science.282.5397.2272","article-title":"Regulation of cocaine reward by CREB","volume":"282","author":"Carlezon","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.tins.2005.06.005","article-title":"The many faces of CREB","volume":"28","author":"Carlezon","year":"2005","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/jpet.105.092304","article-title":"Depressive-like effects of the \u03ba-opioid receptor agonist Salvinorin A on behavior and neurochemistry in rats","volume":"314","author":"Carlezon","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib22","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/0024-3205(89)90518-3","article-title":"Effects of the selective kappa opioid antagonist, nor-binaltorphimine, on electrically-elicited feeding in the rat","volume":"45","author":"Carr","year":"1989","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib23","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.1083968","article-title":"Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene","volume":"301","author":"Caspi","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib24","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1038\/sj.npp.1301659","article-title":"Exposure to the selective kappa agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats","volume":"33","author":"Chartoff","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1124\/mol.108.051417","article-title":"Desipramine reduces stress-activated dynorphin expression and CREB phosphorylation in nucleus accumbens tissue","volume":"75","author":"Chartoff","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0165-1781(93)90084-T","article-title":"Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: a pilot study","volume":"47","author":"Chappell","year":"1993","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1126\/science.6120570","article-title":"Dynorphin is a specific endogenous ligand of the kappa opioid receptor","volume":"215","author":"Chavkin","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib28","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1124\/jpet.103.059394","article-title":"Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations","volume":"308","author":"Chavkin","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1017\/S1461145707008073","article-title":"The effects of pentazocine, a kappa agonist, in patients with mania","volume":"11","author":"Cohen","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s002130050483","article-title":"Activation of midline thalamic nuclei by antipsychotic drugs","volume":"135","author":"Cohen","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0893-133X(01)00277-9","article-title":"Alterations of thalamic activity in schizophrenia and in response to antipsychotic drugs: studies in the legacy of Seymour S. Kety","volume":"25","author":"Cohen","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0896-6273(95)90225-2","article-title":"Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum","volume":"14","author":"Cole","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders","volume":"8","author":"Conn","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1021\/jm00105a027","article-title":"2-(3,4-Dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted-ethyl]-acetamides: the use of conformational analysis in the development of a novel series of potent opioid kappa agonists","volume":"34","author":"Costello","year":"1991","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0361-9230(95)00049-K","article-title":"Short-term cocaine self administration alters striatal gene expression","volume":"37","author":"Daunais","year":"1995","journal-title":"Brain Res Bull"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.05.008_bib37","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0165-6147(00)01799-5","article-title":"Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking","volume":"22","author":"Devi","year":"2001","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib38","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S0022-3565(25)39324-9","article-title":"Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies","volume":"266","author":"Devine","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib39","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","article-title":"Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats","volume":"85","author":"Di Chiara","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib40","first-page":"193","article-title":"Kappa agonist-induced reduction in dopamine release: site of action and tolerance","volume":"78","author":"Donzanti","year":"1992","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib41","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1210\/me.8.3.333","article-title":"Identification of multiple DNA elements regulating basal and protein kinase A-induced transcriptional expression of the rat prodynorphin gene","volume":"8","author":"Douglass","year":"1994","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib42","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bbr.2006.10.002","article-title":"Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze","volume":"176","author":"Drapier","year":"2007","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib43","first-page":"30","article-title":"Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo","volume":"316","author":"Endoh","year":"1992","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib44","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/cns.1987.4.227","article-title":"Kappa-selective opiate antagonist nor-binaltorphimine improves outcome after traumatic spinal cord injury in rats","volume":"4","author":"Faden","year":"1987","journal-title":"Cent Nerv Syst Trauma"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib45","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00008877-200512000-00005","article-title":"Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse","volume":"16","author":"Fantegrossi","year":"2005","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib46","first-page":"32","article-title":"Efficacy issues with antidepressants","volume":"58","author":"Fawcett","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/76061","article-title":"Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses","volume":"25","author":"Filliol","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib48","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1523\/JNEUROSCI.4331-05.2006","article-title":"Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location","volume":"26","author":"Ford","year":"2006","journal-title":"J Neurosci"},{"issue":"Suppl 1","key":"10.1016\/j.pharmthera.2009.05.008_bib49","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1097\/00004714-199704001-00002","article-title":"Pharmacology of antidepressants","volume":"17","author":"Frazer","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0022-3565(25)26705-2","article-title":"Studies on the human addiction liability of 2\u2032-hydroxy-5, 9-dimethyl-2-(3,3-dimethylally)-6, 7-benzomorphan (WIN 20, 228): A weak narcotic antagonist","volume":"143","author":"Fraser","year":"1964","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib51","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.drugalcdep.2006.04.001","article-title":"Pattern of use and subjective effects of Salvia divinorum among recreational users","volume":"85","author":"Gonzalez","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib52","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.163.2.303","article-title":"Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling","volume":"163","author":"Grant","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib53","doi-asserted-by":"crossref","unstructured":"Groer, C. E., Tidgewell, K., Moyer, R. A., Harding, W. W., Rothman, R. B., Prisinzano, T. E., et al. (in press), An Opioid Agonist that does not induce mu opioid receptor\u2013arrestin interactions or receptor internalization. Mol Pharmacol, doi:10.1124\/mol.106.028258.","DOI":"10.1124\/mol.106.028258"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib54","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/0024-3205(82)90209-0","article-title":"Dynorphin: potent analgesic effect in spinal cord of the rat","volume":"31","author":"Han","year":"1982","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib55","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/0024-3205(84)90612-X","article-title":"Analgesia induced by intrathecal injection of dynorphin B in the rat","volume":"34","author":"Han","year":"1984","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib136","first-page":"18","article-title":"Salvia divinorum: clinical and research potential","volume":"13","author":"Hanes","year":"2003","journal-title":"MAPS"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib56","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0006-8993(00)02776-1","article-title":"Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice","volume":"880","author":"Hough","year":"2000","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib57","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1523\/JNEUROSCI.12-02-00483.1992","article-title":"Opioids excite dopamine neurons by hyperpolarization of local interneurons","volume":"12","author":"Johnson","year":"1992","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib58","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1021\/jm9805182","article-title":"Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors","volume":"41","author":"Jones","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib59","doi-asserted-by":"crossref","first-page":"9188","DOI":"10.1016\/j.bmc.2008.09.011","article-title":"Design, synthesis, and structure-activity relationship of novel opioid kappa-agonists","volume":"16","author":"Kawai","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib60","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1176\/ajp.156.6.837","article-title":"Causal relationship between stressful life events and the onset of major depression","volume":"156","author":"Kendler","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib61","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1124\/jpet.107.127415","article-title":"Anxiolytic-like effects of \u03ba-opioid receptor antagonists in behavioral models of unlearned and learned fear in rats","volume":"323","author":"Knoll","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib62","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0893-133X(02)00377-9","article-title":"R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study","volume":"27","author":"Koch","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib63","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0014-2999(85)90431-5","article-title":"[3H]U-69593 a highly selective ligand for the opioid kappa receptor","volume":"109","author":"Lahti","year":"1985","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib64","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0091-3057(91)90210-S","article-title":"Morphine\u2013dopamine interaction: ventral tegmental morphine increases nucleus accumbens dopamine release","volume":"39","author":"Leone","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib65","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/mol.61.1.73","article-title":"Molecular basis of differences in (\u2212)(trans)-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidiny)-cyclohexyl]benzeneacetamide-induced desensitization and phosphorylation between human and rat \u03ba-opioid receptors expressed in Chinese hamster ovary cells","volume":"61","author":"Li","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib66","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0306-4522(03)00397-X","article-title":"Dynorphinergic GABA neurons are a target of both typical and atypical antipsychotic drugs in the nucleus accumbens shell, central amygdaloid nucleus and thalamic central medial nucleus","volume":"121","author":"Ma","year":"2003","journal-title":"Neurosci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib67","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.pnpbp.2005.11.040","article-title":"Expression of noradrenergic \u03b11, serotoninergic 5HT2a and dopaminergic D2 receptors on neurons activated by typical and atypical antipsychotic drugs","volume":"30","author":"Ma","year":"2006","journal-title":"Prog Neuro-Psychopharmacol Biol Psych"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib68","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.046433","article-title":"Antidepressant-like effects of \u03ba-opioid receptor antagonists in the forced swim test in rats","volume":"305","author":"Mague","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib69","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0304-3940(94)90559-2","article-title":"U50,488, a \u03ba-opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats","volume":"181","author":"Maisonneuve","year":"1994","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib70","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0166-2236(95)93876-Y","article-title":"Opioid receptors: past, present and future","volume":"18","author":"Mansour","year":"1995","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib71","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0022-3565(25)23043-9","article-title":"Kappa opioid receptor-mediated regulation of dopaminergic neurons in the rat brain","volume":"256","author":"Manzanares","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib72","doi-asserted-by":"crossref","first-page":"9981","DOI":"10.1523\/JNEUROSCI.23-31-09981.2003","article-title":"Kappa opioid agonists directly inhibit midbrain dopaminergic neurons","volume":"23","author":"Margolis","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib73","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1152\/jn.00855.2004","article-title":"Both kappa and mu opioid agonists inhibit glutamatergic input to ventral tegmental area neurons","volume":"93","author":"Margolis","year":"2005","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib74","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1073\/pnas.0511159103","article-title":"Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex","volume":"103","author":"Margolis","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib75","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF02245878","article-title":"Desmethylimipramine attenuates cocaine withdrawal in rats","volume":"109","author":"Markou","year":"1992","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib76","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-3565(25)30536-7","article-title":"The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog","volume":"197","author":"Martin","year":"1976","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib77","unstructured":"Magnus-Aryitey, G. T., Ruggeri, R. B., (2008). Diaryl ether derivatives as opioid receptors antagonists and their preparation, pharmaceutical compositions and use in the treatment of obesity. Patent application WO2008032156."},{"key":"10.1016\/j.pharmthera.2009.05.008_bib78","unstructured":"Magnus-Aryitey, G. T., Ruggeri, R. B., Thuma, B. A., (2008). Biaryl, bipyridinyl and aryl\u2013pyridinyl derivatives as mu-, kappa-, and delta-opioid receptor antagonist and their preparation and use in the treatment of opioid receptor-mediated diseases. Patent application WO 2008059335."},{"key":"10.1016\/j.pharmthera.2009.05.008_bib79","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/87865","article-title":"The cellular neurobiology of depression","volume":"7","author":"Manji","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib80","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0166-2236(88)90093-8","article-title":"Anatomy of CNS opioid receptors","volume":"11","author":"Mansour","year":"1988","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib81","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1523\/JNEUROSCI.23-13-05674.2003","article-title":"Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses","volume":"23","author":"McLaughlin","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib82","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.npp.1300860","article-title":"Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning","volume":"31","author":"McLaughlin","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib83","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/sj.npp.1300872","article-title":"Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system","volume":"31","author":"McLaughlin","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib84","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0022-3565(24)37657-8","article-title":"Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys","volume":"286","author":"Mello","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib85","doi-asserted-by":"crossref","first-page":"E704","DOI":"10.1208\/aapsj070371","article-title":"Kappa opioid antagonists: past successes and future prospects","volume":"7","author":"Metcalf","year":"2005","journal-title":"Aaps J"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib86","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s00213-004-1878-7","article-title":"Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys","volume":"176","author":"Negus","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib87","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00213-002-1038-x","article-title":"Kappa opioid antagonist effects of the novel KOR antagonist 5\u2032-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys","volume":"163","author":"Negus","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib88","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.biopsych.2005.09.018","article-title":"The mesolimbic dopamine reward circuit in depression","volume":"59","author":"Nestler","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib89","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0006-3223(02)01405-1","article-title":"Preclinical models: status of basic research in depression","volume":"52","author":"Nestler","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib90","doi-asserted-by":"crossref","first-page":"10883","DOI":"10.1523\/JNEUROSCI.22-24-10883.2002","article-title":"Inhibition of CREB or dynorphin in the nucleus accumbens produces an antidepressant-like effect","volume":"22","author":"Newton","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib91","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0006-8993(82)90454-1","article-title":"Reinforcing effects of morphine in the nucleus accumbens","volume":"237","author":"Olds","year":"1982","journal-title":"Brain Res"},{"issue":"Suppl 1","key":"10.1016\/j.pharmthera.2009.05.008_bib92","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0024-3205(83)90569-6","article-title":"A comparative study of the respiratory depressant and analgesic effects of bremazocine, a kappa-agonist","volume":"33","author":"Pazos","year":"1983","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib93","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib94","doi-asserted-by":"crossref","first-page":"7397","DOI":"10.1523\/JNEUROSCI.21-18-07397.2001","article-title":"Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element binding protein expression in nucleus accumbens","volume":"21","author":"Pliakas","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib95","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/0024-3205(87)90585-6","article-title":"Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists","volume":"40","author":"Portoghese","year":"1987","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib96","article-title":"Biphasic effects of the kappa opioid receptor agonist salvinorin A on hedonic state","volume":"34","author":"Potter","year":"2008","journal-title":"Soc Neurosci Abstracts"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib97","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1021\/cr0782269","article-title":"Salvinorin A analogs as probes in opioid pharmacology","volume":"108","author":"Prisinzano","year":"2008","journal-title":"Chem Rev"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib98","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0022-3565(24)38026-7","article-title":"Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor","volume":"288","author":"Remmers","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 1","key":"10.1016\/j.pharmthera.2009.05.008_bib99","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4","article-title":"Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders","volume":"12","author":"Ressler","year":"2000","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib100","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1126\/science.2820058","article-title":"Cocaine receptors on dopamine transporters are related to self-administration of cocaine","volume":"237","author":"Ritz","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib101","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1073\/pnas.182234399","article-title":"Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist","volume":"99","author":"Roth","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib102","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0026-895X(25)08750-4","article-title":"Inhibition by antidepressant drugs of cyclic AMP response element binding protein\/cyclic AMP response element-directed gene transcription","volume":"47","author":"Schwaninger","year":"1995","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib103","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1471-4159.2004.02589.x","article-title":"Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects","volume":"90","author":"Shirayama","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib104","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0378-8741(94)90116-3","article-title":"Salvia divinorum and Salvinorin A: new pharmacologic findings","volume":"43","author":"Siebert","year":"1994","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib105","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/emboj\/17.4.886","article-title":"Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal","volume":"17","author":"Simonin","year":"1998","journal-title":"Embo J"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib106","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00213-002-1102-6","article-title":"Age-related differences in sensitivity to the antinociceptive effects of kappa opioids in adult male rats","volume":"162","author":"Smith","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib107","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0165-6147(03)00066-X","article-title":"Historical review: opioid receptors","volume":"24","author":"Snyder","year":"2003","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib108","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0304-3940(93)90329-J","article-title":"Modulation of morphine-induced sensitization by endogenous kappa opioid systems in the rat","volume":"153","author":"Spanagel","year":"1993","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib109","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1073\/pnas.89.6.2046","article-title":"Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway","volume":"89","author":"Spanagel","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib110","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1021\/jm0000665","article-title":"Potent and selective indolomorphinan antagonists of the kappa-opioid receptor","volume":"43","author":"Stevens","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib111","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0006-8993(02)02894-9","article-title":"Kappa-opioid and NMDA glutamate receptors are differentially targeted within rat medial prefrontal cortex","volume":"946","author":"Svingos","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib112","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1523\/JNEUROSCI.19-05-01804.1999","article-title":"Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell","volume":"19","author":"Svingos","year":"1999","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib113","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1021\/jm00352a005","article-title":"Benzeneacetamide amines: structurally novel non-m mu opioids","volume":"25","author":"Szmuszkovicz","year":"1982","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib114","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1523\/JNEUROSCI.19-02-00610.1999","article-title":"Chronic antidepressant administration increases the expression of cAMP phosphodiesterase 4A and 4B isoforms","volume":"19","author":"Takahashi","year":"1998","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib115","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1021\/jm015521r","article-title":"Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity","volume":"44","author":"Thomas","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib116","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00213-003-1680-y","article-title":"Effects of \u03ba-opioid receptor ligands on intracranial self-stimulation in rats","volume":"172","author":"Todtenkopf","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib117","first-page":"440","article-title":"Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications","volume":"178","author":"Toll","year":"1997","journal-title":"NIDA Res Mono"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib118","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.brainres.2006.03.102","article-title":"Behavioral effects of acute and sub-acute administration of lithium and valproic acid in rats","volume":"1093","author":"Tomasiewicz","year":"2006","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib119","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.biopsych.2008.05.029","article-title":"The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward","volume":"64","author":"Tomasiewicz","year":"2008","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0006-8993(96)01316-9","article-title":"Enhanced CREB phosphorylation and changes in c-Fos and FRA expression in striatum accompany amphetamine sensitization","volume":"749","author":"Turgeon","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib121","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/02791072.1994.10472441","article-title":"Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A","volume":"26","author":"Valdes","year":"1994","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib122","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s11920-006-0050-y","article-title":"The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression","volume":"8","author":"Vergne","year":"2006","journal-title":"Curr Psychiatry Reports"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib123","first-page":"R1527","article-title":"Kappa-opioid antagonist improves cellular bioenergetics and recovery after traumatic brain injury","volume":"261","author":"Vink","year":"1991","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib124","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1527-3458.2003.tb00248.x","article-title":"A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist","volume":"9","author":"Wadenberg","year":"2003","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0022-3565(24)29312-5","article-title":"Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans","volume":"299","author":"Walsh","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib126","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s002130100788","article-title":"Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans","volume":"157","author":"Walsh","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib127","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1124\/jpet.104.073668","article-title":"Comparison of pharmacological activities of three distinct KOR ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo","volume":"312","author":"Wang","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib128","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1124\/jpet.106.118810","article-title":"Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment","volume":"321","author":"Wang","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib129","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/npp.2008.142","article-title":"Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone","volume":"34","author":"Wittmann","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00427414","article-title":"The validity of animal models of depression","volume":"83","author":"Willner","year":"1984","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib131","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1017\/S0140525X00010372","article-title":"Neuroleptics and operant behavior: the anhedonia hypothesis","volume":"5","author":"Wise","year":"1982","journal-title":"Behav Brain Sci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib132","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1037\/0033-295X.94.4.469","article-title":"A psychomotor stimulant theory of addiction","volume":"94","author":"Wise","year":"1987","journal-title":"Psych Rev"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib133","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1016\/j.lfs.2004.07.008","article-title":"Salvinorin A: a novel and highly selective kappa-opioid receptor agonist","volume":"75","author":"Yan","year":"2004","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib134","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0022-3565(24)36877-6","article-title":"Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands","volume":"282","author":"Zhu","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.05.008_bib135","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/275332a0","article-title":"New structural concepts for narcotic antagonists defined in a 4-phenylpiperidine series","volume":"275","author":"Zimmerman","year":"1978","journal-title":"Nature"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725809001119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725809001119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T21:41:34Z","timestamp":1739137294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725809001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":136,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0163725809001119"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2009.05.008","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}